Gene · 5603
Papers1,919
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
81 to 100 of 1,919
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Powerful and accurate detection of temporal gene expression patterns from multi-sample multi-stage single-cell transcriptomics data with TDEseq. | Genome Biol | 2024 | 38622747 | PubTator, text mining | PubMed |
| Pirfenidone ameliorates alcohol-induced promotion of breast cancer in mice. | Front Oncol | 2024 | 38590657 | PubTator, text mining | PubMed |
| CHF6297: a novel potent and selective p38 MAPK inhibitor with robust anti-inflammatory activity and suitable for inhaled pulmonary administration as dry powder. | Front Pharmacol | 2024 | 38549671 | PubTator, text mining | PubMed |
| Human Amniotic MSC Response in LPS-Stimulated Ascites from Patients with Cirrhosis: FOXO1 Gene and Th17 Activation in Enhanced Antibacterial Activation. | Int J Mol Sci | 2024 | 38474048 | PubTator, text mining | PubMed |
| Mitogen-activated protein kinase-guided drug discovery for post-viral and related types of lung disease. | Eur Respir Rev | 2024 | 38417971 | PubTator, text mining | PubMed |
| Phosphorylation of human glioma-associated oncogene 1 on Ser937 regulates Sonic Hedgehog signaling in medulloblastoma. | Nat Commun | 2024 | 38307877 | PubTator, text mining | PubMed |
| LRP11 promotes stem-like T cells via MAPK13-mediated TCF1 phosphorylation, enhancing anti-PD1 immunotherapy. | J Immunother Cancer | 2024 | 38272565 | PubTator, text mining | PubMed |
| p38 Molecular Targeting for Next-Generation Multiple Myeloma Therapy. | Cancers (Basel) | 2024 | 38254747 | PubTator, text mining | PubMed |
| Unexpected inhibition of the lipid kinase PIKfyve reveals an epistatic role for p38 MAPKs in endolysosomal fission and volume control. | Cell Death Dis | 2024 | 38253602 | PubTator, text mining | PubMed |
| Patient-specific signaling signatures predict optimal therapeutic combinations for triple negative breast cancer. | Mol Cancer | 2024 | 38229082 | PubTator, text mining | PubMed |
| Natural products targeting the MAPK-signaling pathway in cancer: overview. | J Cancer Res Clin Oncol | 2024 | 38193944 | PubTator, text mining | PubMed |
| The PB1 and the ZZ domain of the autophagy receptor p62/SQSTM1 regulate the interaction of p62/SQSTM1 with the autophagosome protein LC3B. | Protein Sci | 2024 | 37984441 | PubTator, text mining | PubMed |
| Common and specific proteins and pathways in heart and cerebral ischemia. | J Stroke Cerebrovasc Dis | 2024 | 37944280 | PubTator, text mining | PubMed |
| Canonical and noncanonical Wnt signaling: Multilayered mediators, signaling mechanisms and major signaling crosstalk. | Genes Dis | 2024 | 37588235 | PubTator, text mining | PubMed |
| p38γ/δ activation alters cardiac electrical activity and predisposes to ventricular arrhythmia. | Nat Cardiovasc Res | 2023 | 39196141 | PubTator, text mining | PubMed |
| Chronic Thromboembolic Pulmonary Hypertension: A Review of the Multifaceted Pathobiology. | Biomedicines | 2023 | 38255153 | PubTator, text mining | PubMed |
| Metabolomics-transcriptomics joint analysis: unveiling the dysregulated cell death network and developing a diagnostic model for high-grade neuroblastoma. | Front Immunol | 2023 | 38239355 | PubTator, text mining | PubMed |
| Identification of Differential Circular RNA Expression Profiles and Functional Networks in Human Macrophages Induced by Virulent and Avirulent Mycobacterium tuberculosis Strains. | Int J Mol Sci | 2023 | 38139387 | PubTator, text mining | PubMed |
| p38 Mitogen-Activated Protein Kinase Inhibition of Mesenchymal Transdifferentiated Tumor Cells in Head and Neck Squamous Cell Carcinoma. | Biomedicines | 2023 | 38137525 | PubTator, text mining | PubMed |
| Mir-142-3P regulates MAPK protein family by inhibiting 14-3-3η to enhance bone marrow mesenchymal stem cells osteogenesis. | Sci Rep | 2023 | 38129425 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5603/papers?page=5